Zacks Investment Research downgraded shares of Aratana Therapeutics Inc. (NASDAQ:PETX) from a hold rating to a sell rating in a research note issued to investors on Thursday.

According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “

Several other analysts have also issued reports on PETX. Lake Street Capital reaffirmed a buy rating and set a $15.00 price target on shares of Aratana Therapeutics in a research report on Tuesday, September 6th. Jefferies Group started coverage on shares of Aratana Therapeutics in a report on Friday, August 19th. They issued a buy rating and a $13.00 price objective on the stock. William Blair reiterated an outperform rating on shares of Aratana Therapeutics in a report on Wednesday, August 17th. Barclays PLC decreased their price objective on shares of Aratana Therapeutics from $15.00 to $11.00 and set an overweight rating on the stock in a report on Thursday, August 11th. Finally, Credit Suisse Group AG reiterated a buy rating and issued a $11.00 price objective on shares of Aratana Therapeutics in a report on Wednesday, August 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $11.28.

Aratana Therapeutics (NASDAQ:PETX) traded down 1.11% on Thursday, reaching $8.93. 129,429 shares of the company were exchanged. The firm’s market capitalization is $316.26 million. Aratana Therapeutics has a 12-month low of $2.56 and a 12-month high of $10.73. The stock has a 50 day moving average of $9.28 and a 200 day moving average of $7.45.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.37. Aratana Therapeutics had a negative net margin of 166.67% and a negative return on equity of 17.53%. The firm had revenue of $38.05 million for the quarter, compared to analyst estimates of $15.14 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. Equities analysts anticipate that Aratana Therapeutics will post ($0.78) EPS for the current year.

In other news, insider Ernst Heinen sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $10.00, for a total transaction of $100,000.00. Following the completion of the sale, the insider now owns 115,494 shares of the company’s stock, valued at approximately $1,154,940. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $9.25, for a total transaction of $462,500.00. Following the sale, the insider now directly owns 642,793 shares of the company’s stock, valued at approximately $5,945,835.25. The disclosure for this sale can be found here. Insiders own 6.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in PETX. Franklin Resources Inc. increased its stake in shares of Aratana Therapeutics by 23.7% in the first quarter. Franklin Resources Inc. now owns 5,421,549 shares of the biopharmaceutical company’s stock valued at $29,927,000 after buying an additional 1,037,646 shares during the period. State Street Corp increased its stake in shares of Aratana Therapeutics by 16.5% in the first quarter. State Street Corp now owns 518,187 shares of the biopharmaceutical company’s stock valued at $2,865,000 after buying an additional 73,460 shares during the period. Geode Capital Management LLC increased its stake in shares of Aratana Therapeutics by 1.4% in the first quarter. Geode Capital Management LLC now owns 183,881 shares of the biopharmaceutical company’s stock valued at $1,015,000 after buying an additional 2,550 shares during the period. Mariner Wealth Advisors LLC increased its stake in shares of Aratana Therapeutics by 37.3% in the first quarter. Mariner Wealth Advisors LLC now owns 51,673 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 14,031 shares during the period. Finally, Westend Capital Management LLC increased its stake in shares of Aratana Therapeutics by 37.2% in the first quarter. Westend Capital Management LLC now owns 123,190 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 33,410 shares during the period. 85.56% of the stock is owned by institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

5 Day Chart for NASDAQ:PETX

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.